NCT06991907View on ClinicalTrials.gov

PD-1 Inhibitor Combined With 125I Seed Implantation for Hepatocellular Carcinoma's Extrahepatic Metastasis: Efficacy and Safety

NACompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

January 1, 2020

Primary Completion Date

March 19, 2025

Study Completion Date

March 20, 2025

Conditions
HCC - Hepatocellular Carcinoma125I Seeds Implantation
Interventions
PROCEDURE

125I seed implantation

125I seed implantation

DRUG

PD-1 Inhibitors

PD-1 inhibitors (sintilimab/teriprizumab/camrelizumab) are administered intravenously at a dose of 200 mg once every three weeks. According to the manufacturer's guidelines, the dose is reduced or discontinued based on the severity of adverse effects.

Trial Locations (1)

330029

Jiangxi Cancer Hospital, Nanchang

All Listed Sponsors
lead

Jiangxi Provincial Cancer Hospital

OTHER

NCT06991907 - PD-1 Inhibitor Combined With 125I Seed Implantation for Hepatocellular Carcinoma's Extrahepatic Metastasis: Efficacy and Safety | Biotech Hunter | Biotech Hunter